Tianyuan Bio-Innovation Drug TJ107 (HyLeukin ®) approved by China's State Drug Administration
-
Last Update: 2020-06-11
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
recently, Tianyuan Biotech (Shanghai) LimitedCompany(announced that its newnew drug for cancer immunotherapy,(HyLeukin ®) has been approved by the China NationalMedicines(China NatioMedical Medicine Sinadministration, NMPA) for clinical research approvalto date, TJ107 is the world's first long-acting recombinant human leukocyl-leukin-7 (rhIL-7) in the world to be developed to treat long-acting recombinant human interleukin swastolic disease and cancer induced by chemotherapyTJ107 (HyLeukin)TJ107 (HyLeukin) is a technology based on the optimized design of crystalline hybrid fragments
patented(and built with long-lasting media-7 (IL-7) with long half-life, stability and good developmentabilityIn December 2017, Skyfall Bio and Genexine signed a TJ107 (HyLeukin) cooperation agreement to obtain an exclusive license for the development and commercialization of the project in the Greater China regionthe current preclinical and preliminary clinical results abroad show that TJ107 can increase the number and function of anti-tumor T cellsIt also shows good safety and tolerance
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
